773103-49-4

Upstream product

• 773104-00-0 methyl 3-[(aminocarbonothioyl)amino]-4-methylbenzoate 
• 66211-46-9 (R)-3-amino-1,2-propanediol 
• 773104-01-1 3-(4-hydroxy-2-methylsulfanyl-6-oxo-6H-pyrimidin-1-yl)-4-methyl-benzoic acid methyl ester 
• 773104-02-2 methyl 3-[4-[(2,4-difluorobenzyl)oxy]-2-(methylthio)-6-oxopyrimidin-1(6H)-yl]-4-methylbenzoate 
• 773104-06-6 C₁₉H₁₄F₂N₂O₄ 
• 773104-07-7 3-[5-chloro-4-(2,4-difluorobenzyloxy)-6-oxo-6H-pyrimidin-1-yl]-4-methylbenzoic acid 
• 18595-18-1 3-amino-4-methyl benzoic acid methyl ester 

Relevant academic research and scientific papers

Substituted N-aryl-6-pyrimidinones: A new class of potent, selective, and orally active p38 MAP kinase inhibitors

A novel series of highly potent and selective p38 MAP kinase inhibitors was developed originating from a substituted N-aryl-6-pyrimidinone scaffold. SAR studies coupled with in vivo evaluations in rat arthritis model culminated in the identification of 10 with excellent oral efficacy. Compound 10 exhibited a significantly enhanced dissolution rate compared to 1, translating to a high oral bioavailability (>90%) in rat. In animal studies 10 inhibited LPS-stimulated production of tumor necrosis factor-α in a dose-dependent manner and demonstrated robust efficacy comparable to dexamethasone in a rat streptococcal cell wall-induced arthritis model.